Imaging Approaches for Dementia

References

1. 1.↵
   1. Reitz C,
   2. Brayne C,
   3. Mayeux R

   . Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7:137–52

   CrossRefPubMed
2. 2.↵
   1. Matthews FE,
   2. Brayne C,
   3. Lowe J,
   4. et al

   . Epidemiological pathology of dementia: attributable-risks at death in the medical research council cognitive function and ageing study. PLoS Med 2009;6:e1000180

   CrossRef
3. 3.↵
   1. Knopman DS,
   2. DeKosky ST,
   3. Cummings JL,
   4. et al

   . Practice parameter: diagnosis of dementia (an evidence-based review. Report of the quality standards subcommittee of the American Academy of Neurology). Neurology 2001;56:1143–53

   CrossRefPubMed
4. 4.↵
   1. Matsuda H

   . Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med 2007;48:1289–300
5. 5.↵
   1. Jack CR Jr.,
   2. Bernstein MA,
   3. Borowski BJ,
   4. et al

   . Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2010;6:212–20

   CrossRefPubMed
6. 6.↵
   1. Dubois B,
   2. Feldman HH,
   3. Jacova C,
   4. et al

   . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–46

   CrossRefPubMed
7. 7.↵
   1. McKhann GM,
   2. Knopman DS,
   3. Chertkow H,
   4. et al

   . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263–69

   CrossRefPubMed
8. 8.↵
   1. Alzheimer A,
   2. Stelzmann RA,
   3. Schnitzlein HN,
   4. et al

   . An English translation of Alzheimer's 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde.” Clin Anat 1995;8:429–31

   CrossRefPubMed
9. 9.↵
   1. Braak H,
   2. Braak E

   . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59

   CrossRefPubMed
10. 10.↵
    1. Bertram L,
    2. Tanzi RE

    . Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768–78

    CrossRefPubMed
11. 11.↵
    1. Li YJ,
    2. Hauser MA,
    3. Scott WK,
    4. et al

    . Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 2004;62:2005–09

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Jack CR Jr.,
    2. Dickson DW,
    3. Parisi JE,
    4. et al

    . Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750–57

    CrossRefPubMed
13. 13.↵
    1. Ikram MA,
    2. Vrooman HA,
    3. Vernooij MW,
    4. et al

    . Brain tissue volumes in relation to cognitive function and risk of dementia. Neurobiol Aging 2010;31:378–86

    CrossRefPubMed
14. 14.↵
    1. Jack CR Jr.,
    2. Shiung MM,
    3. Gunter JL,
    4. et al

    . Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591–600

    CrossRefPubMed
15. 15.↵
    1. Barnes J,
    2. Bartlett JW,
    3. van de Pol LA,
    4. et al

    . A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 2009;30:1711–23

    CrossRefPubMed
16. 16.↵
    1. Staff RT,
    2. Murray AD,
    3. Ahearn T,
    4. et al

    . Brain volume and survival from age 78 to 85: the contribution of Alzheimer-type magnetic resonance imaging findings. J Am Geriatr Soc 2010;58:688–95

    CrossRefPubMed
17. 17.↵
    1. Pruessner JC,
    2. Li LM,
    3. Serles W,
    4. et al

    . Volumetry of hippocampus and amygdala with high-resolution MRI and three-dimensional analysis software: minimizing the discrepancies between laboratories. Cereb Cortex 2000;10:433–42

    CrossRefPubMed
18. 18.↵
    1. Langbaum JB,
    2. Chen K,
    3. Lee W,
    4. et al

    . Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009;45:1107–16

    CrossRefPubMed
19. 19.↵
    1. Wyper D,
    2. Teasdale E,
    3. Patterson J,
    4. et al

    . Abnormalities in rCBF and computed tomography in patients with Alzheimer's disease and in controls. Br J Radiol 1993;66:23–27

    CrossRefPubMed
20. 20.↵
    1. Samuraki M,
    2. Matsunari I,
    3. Chen WP,
    4. et al

    . Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2007;34:1658–69

    CrossRefPubMed
21. 21.↵
    1. Jack CR Jr.,
    2. Knopman DS,
    3. Jagust WJ,
    4. et al

    . Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:
22. 22.↵
    1. Klunk WE,
    2. Engler H,
    3. Nordberg A,
    4. et al

    . Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306–19

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Wong DF,
    2. Rosenberg PB,
    3. Zhou Y,
    4. et al

    . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51:913–20

    CrossRefPubMed
24. 24.↵
    1. Vandenberghe R,
    2. Van Laere K,
    3. Ivanoiu A,
    4. et al

    . 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319–29

    CrossRefPubMed
25. 25.↵
    1. Jack CR Jr.,
    2. Wiste HJ,
    3. Vemuri P,
    4. et al

    . Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336–48

    CrossRefPubMed
26. 26.↵
    1. Rabinovici GD,
    2. Furst AJ,
    3. Alkalay A,
    4. et al

    . Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010;133:512–28

    CrossRefPubMed
27. 27.↵
    1. Kadir A,
    2. Marutle A,
    3. Gonzalez D,
    4. et al

    . Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh compound B positron emission tomography patient with Alzheimer's disease. Brain 2011;134:301–17

    CrossRefPubMed
28. 28.↵
    1. Rabinovici GD,
    2. Jagust WJ

    . Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21:117–28

    PubMed
29. 29.↵
    1. Apostolova LG,
    2. Thompson PM,
    3. Green AE,
    4. et al

    . 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp 2010;31:786–97

    CrossRefPubMed
30. 30.↵
    1. Leow AD,
    2. Yanovsky I,
    3. Parikshak N,
    4. et al

    . Alzheimer's Disease Neuroimaging Initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009;45:
31. 31.↵
    1. Walhovd KB,
    2. Fjell AM,
    3. Brewer J,
    4. et al

    . Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol 2010;31:347–54

    CrossRefPubMed
32. 32.↵
    1. Strozyk D,
    2. Dickson DW,
    3. Lipton RB,
    4. et al

    . Contribution of vascular pathology to the clinical expression of dementia. Neurobiol Aging 2010;31:1710–20

    CrossRefPubMed
33. 33.↵
    1. Fazekas F,
    2. Chawluk JB,
    3. Alavi A,
    4. et al

    . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:
34. 34.↵
    1. Scheltens P,
    2. Barkhof F,
    3. Leys D,
    4. et al

    . A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7–12

    CrossRefPubMed
35. 35.↵
    1. de Boer R,
    2. Vrooman HA,
    3. van der Lijn F,
    4. et al

    . White matter lesion extension to automatic brain tissue segmentation on MRI. Neuroimage 2009;45:1151–61

    CrossRefPubMed
36. 36.↵
    1. Murray AD,
    2. Staff RT,
    3. Shenkin SD,
    4. et al

    . Brain white matter hyperintensities: relative importance of vascular risk factors in nondemented elderly people. Radiology 2005;237:251–57

    CrossRefPubMed
37. 37.↵
    1. Murray AD,
    2. Staff RT,
    3. McNeil CJ,
    4. et al

    . Brain lesions, hypertension and cognitive ageing in the 1921 and 1936 Aberdeen birth cohorts. Age (Dordr) 2012;34:451–59

    CrossRefPubMed
38. 38.↵
    1. Leaper SA,
    2. Murray AD,
    3. Lemmon HA,
    4. et al

    . Neuropsychologic correlates of brain white matter lesions depicted on MR images: 1921 Aberdeen birth cohort. Radiology 2001;221:51–55

    CrossRefPubMed
39. 39.↵
    1. Gunning-Dixon FM,
    2. Raz N

    . The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 2000;14:224–32

    CrossRefPubMed
40. 40.↵
    1. Debette S,
    2. Markus HS

    . The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666

    CrossRefPubMed
41. 41.↵
    1. Kearney-Schwartz A,
    2. Rossignol P,
    3. Bracard S,
    4. et al

    . Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke 2009;40:1229–36

    CrossRefPubMed
42. 42.
    1. Raz N,
    2. Rodrigue KM,
    3. Kennedy KM,
    4. et al

    . Vascular health and longitudinal changes in brain and cognition in middle-aged and older adults. Neuropsychology 2007;21:149–57

    CrossRefPubMed
43. 43.↵
    1. Fischer P,
    2. Krampla W,
    3. Mostafaie N,
    4. et al

    . VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly. J Neural Transm Suppl 2007: 181–88
44. 44.↵
    1. Jagust WJ,
    2. Zheng L,
    3. Harvey DJ,
    4. et al

    . Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008;63:72–80

    CrossRefPubMed
45. 45.↵
    1. Doubal FN,
    2. MacLullich AM,
    3. Ferguson KJ,
    4. et al

    . Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 2010;41:450–54

    CrossRefPubMed
46. 46.↵
    1. Vernooij MW,
    2. de Groot M,
    3. van der Lugt A,
    4. et al

    . White matter atrophy and lesion formation explain the loss of structural integrity of white matter in aging. Neuroimage 2008;43:470–77

    CrossRefPubMed
47. 47.↵
    1. Poels MM,
    2. Vernooij MW,
    3. Ikram MA,
    4. et al

    . Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke 2010;41 (10 suppl): S103–06

    CrossRefPubMed
48. 48.↵
    1. Brickman AM,
    2. Muraskin J,
    3. Zimmerman ME

    . Structural neuroimaging in Alzheimer's disease: do white matter hyperintensities matter? Dialogues Clin Neurosci 2009;11:181–90

    PubMed
49. 49.↵
    1. Mackenzie IR,
    2. Neumann M,
    3. Bigio EH,
    4. et al

    . Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010;119:1–4

    CrossRefPubMed
50. 50.↵
    1. Seeley WW,
    2. Crawford RK,
    3. Zhou J,
    4. et al

    . Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62:42–52

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Rabinovici GD,
    2. Seeley WW,
    3. Kim EJ,
    4. et al

    . Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2007;22:474–88

    CrossRefPubMed
52. 52.↵
    1. Panegyres PK,
    2. Rogers JM,
    3. McCarthy M,
    4. et al

    . Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol 2009;9:41

    CrossRefPubMed
53. 53.↵
    1. Davatzikos C,
    2. Resnick SM,
    3. Wu X,
    4. et al

    . Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage 2008;41:1220–27
54. 54.↵
    1. McKeith IG,
    2. Dickson DW,
    3. Lowe J,
    4. et al

    . Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863–72

    CrossRefPubMedWeb of Science
55. 55.↵
    1. Zaccai J,
    2. Brayne C,
    3. McKeith I,
    4. et al

    . Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008;70:1042–48

    PubMed
56. 56.↵
    1. Leverenz JB,
    2. Quinn JF,
    3. Zabetian C,
    4. et al

    . Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem 2009;9:903–12

    PubMed
57. 57.↵
    1. Rowe CC,
    2. Ng S,
    3. Ackermann U,
    4. et al

    . Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718–25

    CrossRefPubMedWeb of Science
58. 58.↵
    1. Gomperts SN,
    2. Rentz DM,
    3. Moran E,
    4. et al

    . Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903–10
59. 59.↵
    1. Ishii K,
    2. Imamura T,
    3. Sasaki M,
    4. et al

    . Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998;51:125–30

    CrossRefPubMed
60. 60.↵
    1. Teune LK,
    2. Bartels AL,
    3. de Jong BM,
    4. et al

    . Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010;25:2395–404

    CrossRefPubMed
61. 61.↵
    1. Ishii K,
    2. Soma T,
    3. Kono AK,
    4. et al

    . Comparison of regional brain volume and glucose metabolism between patients with mild dementia with Lewy bodies and those with mild Alzheimer's disease. J Nucl Med 2007;48:704–11

    CrossRefPubMed
62. 62.↵
    1. Booij J,
    2. Speelman JD,
    3. Horstink MW,
    4. et al

    . The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266–72

    CrossRefPubMed
63. 63.↵
    1. Staff RT,
    2. Ahearn TS,
    3. Wilson K,
    4. et al

    . Shape analysis of 123I-N-omega-fluoropropyl-2-beta-carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes. Nucl Med Commun 2009;30:194–201

    CrossRefPubMed
64. 64.↵
    1. Eshuis SA,
    2. Jager PL,
    3. Maguire RP,
    4. et al

    . Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging 2009;36:454–62

    CrossRefPubMed
65. 65.↵
    1. Walker Z,
    2. Jaros E,
    3. Walker RW,
    4. et al

    . Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176–81

    CrossRefPubMed
66. 66.↵
    1. Orimo S,
    2. Amino T,
    3. Itoh Y,
    4. et al

    . Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005;109:583–88

    CrossRefPubMed
67. 67.↵
    1. Cousins DA,
    2. Burton EJ,
    3. Burn D,
    4. et al

    . Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology 2003;61:1191–95

    CrossRefPubMed
68. 68.↵
    1. Breen DP,
    2. Rowe JB,
    3. Barker RA

    . Role of brain imaging in early parkinsonism. BMJ 2011;342:d638

    CrossRefPubMed
69. 69.↵
    1. Rossor MN,
    2. Fox NC,
    3. Mummery CJ,
    4. et al

    . The diagnosis of young-onset dementia. Lancet Neurol 2010;9:793–806

    CrossRefPubMed
70. 70.↵
    1. Flanagan EP,
    2. McKeon A,
    3. Lennon VA,
    4. et al

    . Autoimmune dementia: clinical course and predictors of immunotherapy response. 2010;85:881–97
71. 71.↵
    1. Titulaer MJ,
    2. Soffietti R,
    3. Dalmau J,
    4. et al

    . Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18:19-e3

    PubMed
72. 72.↵
    1. Josephs KA,
    2. Whitwell JL,
    3. Knopman DS,
    4. et al

    . Two distinct subtypes of right temporal variant frontotemporal dementia. Neurology 2009;73:1443–50

    CrossRefPubMed
73. 73.↵
    1. Heath CA,
    2. Cooper SA,
    3. Murray K,
    4. et al

    . Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol 2010;67:761–70

    CrossRefPubMed
74. 74.↵
    1. Wu HM,
    2. Lu CS,
    3. Huang CC,
    4. et al

    . Asymmetric involvement in sporadic Creutzfeldt-Jakob disease: clinical, brain imaging, and electroencephalographic studies. Eur Neurol 2010;64:74–79

    CrossRefPubMed
75. 75.↵
    1. Collie DA,
    2. Summers DM,
    3. Sellar RJ,
    4. et al

    . Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. AJNR Am J Neuroradiol 2003;24:1560–69

    PubMed
76. 76.↵
    1. Kallenberg K,
    2. Schulz-Schaeffer WJ,
    3. Jastrow U,
    4. et al

    . Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. AJNR Am J Neuroradiol 2006;27:1459–62

    PubMed
77. 77.↵
    1. Senocak E,
    2. Oguz KK,
    3. Ozgen B,
    4. et al

    . Imaging features of CNS involvement in AIDS. Diagn Interv Radiol 2010;16:193–200

    PubMed
78. 78.↵
    1. Mohamed MA,
    2. Lentz MR,
    3. Lee V,
    4. et al

    . Factor analysis of proton MR spectroscopic imaging data in HIV infection: metabolite-derived factors help identify infection and dementia. Radiology 2010;254:577–86

    CrossRefPubMed
79. 79.↵
    1. Waiter GD,
    2. Fox HC,
    3. Murray AD,
    4. et al

    . Is retaining the youthful functional anatomy underlying speed of information processing a signature of successful cognitive ageing? An event-related fMRI study of inspection time performance. Neuroimage 2008;41:581–95

    CrossRefPubMed
80. 80.↵
    1. Mellon EA,
    2. Pilkinton DT,
    3. Clark CM,
    4. et al

    . Sodium MR imaging detection of mild Alzheimer disease: preliminary study. AJNR Am J Neuroradiol 2009;30:978–84

    CrossRefPubMed
81. 81.↵
    1. Staff RT,
    2. Murray AD,
    3. Deary IJ,
    4. et al

    . What provides cerebral reserve? Brain 2004;127:1191–99

    CrossRefPubMed
82. 82.↵
    1. Wischik C,
    2. Staff R

    . Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of tau-aggregation inhibitor therapy. J Nutr Health Aging 2009;13:367–69

    CrossRefPubMed
83. 83.↵
    1. Filley CM,
    2. Anderson CA

    . Dementia: five new things. Neurology 2011;76:S26–30